Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 9 of 40 · 1914 articles
The report highlights a serious drug-related complication (pancytopenia/myelosuppression and hair loss) in a patient treated with azathioprine plus sulfasalazine for ulcerative colitis, suggesting clinicians and patients...
Children with IBD and their caregivers may be interested in subcutaneous infliximab as an alternative to regular IV infusions because this review suggests it can maintain drug levels and remission after switching, with...
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
New computational tools that tie gene-expression to metabolic flux could help researchers identify metabolic pathways or biomarkers linked to ulcerative colitis, which might eventually inform research on disease...
The paper identifies subtype-specific changes in enteric glial cells and mast cell activity in microscopic colitis and shows some treatment-associated reductions after budesonide; that helps explain disease biology and...
The study suggests that serum zinc by itself may not be a reliable indicator of endoscopic inflammation in UC; nutritional status and inflammation (for example albumin and CRP) can confound zinc levels.
Work-related productivity loss was common in this study and linked to both clinical (disease activity, strictures, fatigue) and psychosocial factors (anxiety, depression, self-efficacy, social support).
The study tests a mental-health program adapted for people with IBD, comparing therapist-led versus self-directed online delivery — findings could influence access to psychosocial care options for patients with anxiety...
This trial investigates a new oral medication (PALI-2108) for moderate-to-severe ulcerative colitis and could expand treatment options if later trials show benefit and safety. The study focuses on clinical remission at...
Researchers tested whether alpha-lipoic acid — an antioxidant with potential anti-inflammatory effects — can improve symptoms and quality of life when added to standard mesalamine treatment for mild-to-moderate...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from BMC Gastroenterology.
Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.
The review suggests baseline corticosteroid use may change how well some advanced UC therapies work, especially IL-23 inhibitors and S1P modulators, which could affect treatment choices and trial reporting.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
An animal study found two probiotic strains reduced inflammation and inflammasome markers in an experimental ulcerative colitis model, which could inform veterinary treatments and early-stage research relevant to IBD.
Cure8 could only read part of this source from American Journal of Therapeutics, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Infliximab, and Ustekinumab.
People with IBD are at higher risk for shingles; this study suggests the recombinant zoster vaccine reduces that risk and did not increase short-term IBD flares in the populations studied. That could inform vaccine...
This study provides real-world data suggesting the oral α4-integrin antagonist carotegrast methyl can improve patient-reported stool frequency and rectal bleeding in many people with ulcerative colitis who did not...
The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...
Fatigue greatly affects quality of life for people with IBD even in remission; if effective and scalable, a mobile CBT program could offer accessible symptom support. The trial will also examine engagement factors...
Self-management programs that teach cognitive behavioral strategies, symptom tracking, relaxation, sleep and diet skills could help people with IBD manage symptoms and day-to-day quality of life without relying solely on...
This press release announces upcoming presentations of early clinical and biomarker data for PALI-2108, a gut‑targeted oral PDE4 prodrug being developed for UC and Crohn’s disease. Patients and clinicians may see new...
Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.
Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...
The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...
This study suggests that even when people with IBD are in clinical and biological remission on long-term biologic therapy, their gut microbiome composition and inferred functions can still differ from laboratory...
AI-assisted detection tools and disease-specific optical classifications could improve lesion detection and real-time characterization during UC surveillance, potentially affecting surveillance accuracy and...
If you or your clinician are considering switching from IV to subcutaneous vedolizumab, this multicentre cohort suggests most patients (about 84%) remain on the subcutaneous formulation at one year. The switch appears...
The case links thymic hyperplasia, thyroid autoimmunity, and severe UC with colorectal neoplasia, suggesting possible shared immune dysregulation that might interest patients and clinicians, but it does not support...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, and Complications. The original article is from Canadian Medical Association Journal.
A rare but serious neurological complication (Guillain–Barré syndrome) occurred alongside a severe UC flare after abrupt vedolizumab withdrawal, so people with UC should be aware that sudden neurologic weakness needs...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
This study describes a novel, non‑drug HA‑based nano‑assembly that targets inflammatory M1 macrophages and reshapes the colonic immune environment in mouse models of ulcerative colitis — a potential new therapeutic...
New Phase II trials test whether a gut-activated oral PDE4 inhibitor can treat moderate-to-severe ulcerative colitis and Crohn’s while avoiding systemic PDE4 tolerability issues; positive Phase II results could add a new...
This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...
This project targets epithelial repair — a mechanism not directly addressed by most current IBD drugs — and reports early human safety/tolerability data, so it could lead to a new oral therapy for inducing and...
Malnutrition and impaired growth are common at diagnosis in paediatric IBD—especially Crohn’s disease—and identifying these issues early can guide nutrition and treatment planning. Most underweight children in this study...
Cure8 found this source from jo24.net, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Symptoms and flares. Open the original article for the full...
Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.
The study shows pouchitis is a frequent postoperative problem in children after RPC‑IPAA and that many will still require advanced IBD medications, so surgery may not end medical therapy needs.
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...
Consistent, accurate endoscopic scoring matters for treatment decisions and trial outcomes in pediatric IBD. If focused training meaningfully improves scoring—especially for SES‑CD—it could reduce variability in clinical...
People with Sjögren syndrome or clinicians caring for them may be interested because genetic data suggest Sjögren syndrome could modestly raise gastric ulcer risk and — unexpectedly — associate with lower IBS risk, while...
Researchers are exploring ways to durably modulate macrophages in ulcerative colitis because persistent pro-inflammatory macrophages sustain tissue inflammation and impair healing.
This study compares first‑line vedolizumab versus TNF antagonist strategies in biologic‑naive ulcerative colitis patients over multiple years — information that could affect treatment choice and expectations about...
Finding reliable diagnostic biomarkers could help detect UC earlier and clarify immune mechanisms that drive disease; GPR97 is proposed here as such a marker and a possible immunomodulatory target, which may interest...
Spatial mapping of immune niches in refractory UC identified tissue signatures (neutrophil-rich ulcer-bed niches and TLS/plasma-cell programmes) that were associated with failure to respond to biologic drugs across adult...
This review reframes IBD as a systemic disease influenced by gut microbes, metabolism, and immune interactions — which matters because it points toward better ways to stratify patients, monitor disease, and personalize...
